Key result
Intrathrombus NETosis markers track distinct prognostic phenotypes spanning collateral circulation, functional recovery, and survival.
Why the study?
Immunothrombosis in large-vessel-occlusion acute ischemic stroke is recognized, but the clinical relevance of intrathrombus NETosis markers versus plasma markers remains unclear.
Do intrathrombus NETosis markers identify clinically distinct phenotypes and correlate with circulating plasma markers in patients with LVO-AIS treated with mechanical thrombectomy?
Cohort (n=160)
Do intrathrombus NETosis markers identify clinically distinct phenotypes and correlate with circulating plasma markers in patients with LVO-AIS treated with mechanical thrombectomy?
Direct histological assessment of retrieved thrombi provides critical prognostic information regarding functional recovery and survival that is not captured by circulating plasma biomarkers.
Intrathrombus NET markers may stratify thrombectomy outcomes; hypothesis-generating and should not yet change practice.
Background Immunothrombosis is increasingly recognized in large-vessel-occlusion acute ischemic stroke (LVO-AIS), yet most biomarker studies infer thrombus biology from circulating neutrophil extracellular trap (NET) markers or from pre-defined thrombus subtypes. We prospectively studied 160 patients with anterior-circulation LVO-AIS treated with mechanical thrombectomy to determine whether intrathrombus NETosis markers identify thrombus phenotypes with distinct clinical trajectories, and whether plasma NETosis biomarkers reflect the molecular composition of thrombi. Methods Thrombi underwent quantitative histopathology and immunohistochemistry for citrullinated histone H3 (CitH3), neutrophil elastase (NE) and CD61. Thrombi were analyzed without prior etiological or histological stratification, and intrathrombus markers were dichotomized at cohort medians (CitH3 6.62%, NE 3.95%, CD61 23.09%) to define internally standardized candidate phenotypes. Associations with thrombus composition, collateral circulation (Tan 2-3), 3-month functional independence (modified Rankin Scale 2 or less) and long-term mortality were assessed by correlation analyses and progressively adjusted multivariable models, with cross-compartment correlations corrected by the Benjamini-Hochberg false discovery rate (FDR). Results Intrathrombus markers defined prognostically distinct phenotypes: CD61 tracked functional recovery, NE preserved collateral circulation and CitH3 long-term survival, each remaining significant after multivariable adjustment. Circulating NE, myeloperoxidase and leukocyte count instead tracked the macroscopic red-blood-cell-fibrin composition of retrieved thrombi. Cross-compartment concordance was limited: after FDR correction the only significant plasma-thrombus association was an inverse correlation between plasma cell-free DNA and intrathrombus NE, and no intrathrombus marker correlated positively with its circulating counterpart. Conclusions Local immunothrombotic signatures therefore provide clinically relevant information not captured by plasma markers, and median-defined intrathrombus thresholds represent hypothesis-generating cutoffs for external validation and NET-targeted treatment stratification.
No takes yet. Share an insight, caveat, or question.
Díaz-Benito et al. (2026) conducted a cohort in Anterior-circulation large-vessel-occlusion acute ischemic stroke (LVO-AIS) (n=160). Intrathrombus NETosis markers (CitH3, NE, CD61) vs. Cohort medians (CitH3 6.62%, NE 3.95%, CD61 23.09%) was evaluated on Thrombus composition, collateral circulation, 3-month functional independence, and long-term mortality. Intrathrombus NETosis markers defined distinct prognostic phenotypes, with CD61 tracking functional recovery, NE preserving collateral circulation, and CitH3 predicting long-term survival.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: